Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from ImmuPharma ( (GB:IMM) ).
ImmuPharma PLC has announced the promotion of Dr. Sébastien Goudreau to Chief Scientific Officer and Dr. Laura Mauran-Ambrosino to Head of Research and Development, coinciding with the filing of a new patent for their lead asset, P140. These appointments are seen as pivotal for the company’s strategy to partner and commercialize its product portfolio, particularly P140, highlighting the importance of having a strong R&D team for future commercial negotiations.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company that focuses on discovering and developing peptide-based therapeutics. The company’s portfolio includes novel peptide therapeutics targeting autoimmune diseases and anti-infectives.
Average Trading Volume: 2,184,678
Technical Sentiment Signal: Sell
Current Market Cap: £11.12M
Learn more about IMM stock on TipRanks’ Stock Analysis page.